Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment

Key Inclusion Criteria:

- Have a diagnosis of RA (2010 ACR/EULAR criteria for RA), and are ACR functional class
I-III.

- Have ≥ 6 swollen joints (from a swollen joint count based on 66 joints (SJC66)) and ≥6
tender joints (from a tender joint count based on 68 joints (TJC68)) at screening and
Day 1

- Ongoing treatment with a stable prescription of 1 or 2 csDMARDs

- Have received at least one biologic disease modifying antirheumatic drug (bDMARD) for
the treatment of RA to which they have had an inadequate response or intolerance

Key Exclusion Criteria:

- Previous treatment with any janus kinase (JAK) inhibitor

NOTE: Other protocol Inclusion/ Exclusion criteria may apply.